Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Study Assessing the Efficacy of Tocilizumab (TCZ) in Refractory Uveitis associated to Extraocular Manifestations due to Behcet's disease (BD)

Trial Profile

A Multicenter Study Assessing the Efficacy of Tocilizumab (TCZ) in Refractory Uveitis associated to Extraocular Manifestations due to Behcet's disease (BD)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary) ; Tocilizumab (Primary)
  • Indications Uveitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Feb 2018 Results evaluating efficacy of tocilizumab in refractory uveitis associated extraocular manifestations published in the Rheumatology
    • 13 Dec 2017 New trial record
    • 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top